Dealbreaker on MSN
Neurocrine’s $2.9B Soleno buyout brings what could become its next blockbuster drug
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease ...
Neurocrine Biosciences is in advanced talks to acquire Soleno Therapeutics for just over $2.5 billion, or low-to-mid $50s per ...
What is the CAMEO organoid sensor? Researchers have created a low-cost, carbon nanotube-based microelectrode array to monitor ...
Researchers have demonstrated a new class of low-cost, scalable sensors that can be used to monitor electrical activity in ...
Researchers have demonstrated a new class of low-cost, scalable sensors that can be used to monitor electrical activity in ...
Wondering what really causes borderline PD? New neuroscience discoveries suggest that genetics and brain irregularities may ...
The OCU410ST Phase 2/3 pivotal confirmatory trial represents Ocugen’s second late-stage clinical program. Ocugen plans to ...
Advanced genetic testing could help erase significant disparities in breast cancer survival rates between white and Black ...
Everyone’s favorite little blue pill may offer more than just a boost in the bedroom. New research suggests the erectile dysfunction drug Viagra could help treat a devastating neurological disorder ...
BEAVERTON, Oregon — A Beaverton family that has spent years searching for a replacement gene for their son’s rare genetic disorder says they are seeing encouraging progress. Linda and Tommy Pham say ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results